CRIS Current Research Information System

GUADAGNUOLO, VIVIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.377
AS - Asia 5.886
EU - Europa 4.759
AF - Africa 430
SA - Sud America 284
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 17.755
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.291
VN - Vietnam 1.838
SG - Singapore 1.516
CN - Cina 1.359
GB - Regno Unito 1.279
SE - Svezia 701
DE - Germania 654
IT - Italia 604
HK - Hong Kong 354
FR - Francia 312
IN - India 270
RU - Federazione Russa 216
BR - Brasile 193
IE - Irlanda 182
NL - Olanda 182
JP - Giappone 112
TG - Togo 110
ZA - Sudafrica 107
UA - Ucraina 99
NG - Nigeria 96
EE - Estonia 92
FI - Finlandia 91
CH - Svizzera 86
CI - Costa d'Avorio 70
KR - Corea 63
BG - Bulgaria 61
CA - Canada 61
BE - Belgio 53
JO - Giordania 49
AR - Argentina 46
GR - Grecia 41
PH - Filippine 41
IQ - Iraq 34
BD - Bangladesh 33
IR - Iran 30
TH - Thailandia 28
ID - Indonesia 26
TR - Turchia 21
ES - Italia 20
PL - Polonia 20
AT - Austria 18
PK - Pakistan 18
SC - Seychelles 18
MX - Messico 16
UZ - Uzbekistan 16
TW - Taiwan 14
SA - Arabia Saudita 12
EC - Ecuador 9
LB - Libano 9
CL - Cile 8
PE - Perù 8
PY - Paraguay 8
AU - Australia 7
EU - Europa 7
MY - Malesia 7
CO - Colombia 6
CZ - Repubblica Ceca 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
HR - Croazia 5
LT - Lituania 5
MA - Marocco 5
MK - Macedonia 5
PT - Portogallo 5
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
ET - Etiopia 3
PS - Palestinian Territory 3
RS - Serbia 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AL - Albania 2
CY - Cipro 2
DZ - Algeria 2
GY - Guiana 2
HN - Honduras 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
QA - Qatar 2
SI - Slovenia 2
TM - Turkmenistan 2
BH - Bahrain 1
BW - Botswana 1
DK - Danimarca 1
DM - Dominica 1
GE - Georgia 1
GH - Ghana 1
JM - Giamaica 1
Totale 17.747
Salva come PNG Salva come JPEG
Città #
Southend 1.164
Singapore 1.062
Ashburn 701
Dong Ket 660
Chandler 605
Fairfield 539
Ann Arbor 374
Hong Kong 339
Houston 318
Beijing 294
San Jose 294
Ho Chi Minh City 273
Wilmington 269
Woodbridge 265
Seattle 264
Hanoi 236
Santa Clara 209
Cambridge 204
Princeton 200
Dublin 181
Boardman 144
Bologna 131
Lomé 110
Westminster 101
Tokyo 100
Nanjing 97
Lauterbourg 95
New York 95
Padova 94
Hefei 87
Medford 86
Los Angeles 83
Bern 75
Helsinki 74
Abidjan 70
Abeokuta 61
Sofia 60
Frankfurt am Main 57
Munich 53
Brussels 51
Berlin 48
Amman 47
Bremen 46
Shenyang 46
Saint Petersburg 45
Da Nang 44
Nanchang 39
Haiphong 38
Dallas 36
Redondo Beach 36
Redwood City 36
Redmond 35
Shanghai 35
Buffalo 34
Falls Church 34
Seoul 34
Hebei 33
San Diego 33
Florence 32
Jinan 32
São Paulo 32
Toronto 32
Changsha 30
Turin 27
Milan 26
Guangzhou 24
Jiaxing 24
Tianjin 24
Zhengzhou 23
Falkenstein 21
London 21
Council Bluffs 20
Mountain View 20
Norwalk 19
Hangzhou 18
Orem 18
Hyderabad 17
Turku 17
Baghdad 16
Jakarta 16
Hải Dương 15
Paris 14
Rome 14
Haikou 13
Jacksonville 13
Brooklyn 12
Chengdu 12
Johannesburg 12
Ningbo 12
Phoenix 12
Vienna 12
Bangkok 11
Chennai 11
Düsseldorf 11
Montreal 11
Roubaix 11
San Francisco 11
Amsterdam 10
Bühl 10
Kunming 10
Totale 11.620
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 381
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 291
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 289
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 281
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 257
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 253
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 249
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 246
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 240
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 230
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 230
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 228
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
A case report of acute myeloid leukemia and neurofibromatosis 1 220
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 217
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 213
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 208
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 201
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 200
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 198
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 197
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 196
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 196
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 195
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 193
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 191
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 190
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 188
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 186
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 186
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 186
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 185
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 184
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 184
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 181
Clec12a: A new AML stem cell-associated antigen 177
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 177
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 176
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 174
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 173
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 169
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 167
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 163
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 162
SNP array reveals a new deletion of JAK2 in AML patients 162
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 160
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 158
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 158
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 158
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 157
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 154
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 154
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 153
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 153
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 153
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 152
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 151
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 150
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 149
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 146
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 146
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study 146
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 143
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 142
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 141
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 140
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 140
Gene expression signature of aneuploidy in acute myeloid leukemia 139
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 137
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 137
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 134
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 132
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 131
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 130
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 128
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 128
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 127
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 125
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 125
null 123
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 120
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 120
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 116
Molecular Characterization of PAX5 alterations in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) 115
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 107
IL-17/IL-10 double-producing T cells: New link between infections, immunosuppression and acute myeloid leukemia 97
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells 91
Totale 17.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.058 0 0 0 0 0 0 0 0 0 86 83 889
2021/20222.175 188 54 115 185 252 142 58 117 130 155 399 380
2022/20232.493 318 392 106 356 180 196 78 117 392 55 181 122
2023/2024653 28 102 23 61 35 171 52 43 50 28 26 34
2024/20252.244 91 360 183 163 286 76 203 78 19 250 84 451
2025/20264.823 440 303 381 300 624 265 484 202 1.376 448 0 0
Totale 18.097